PetMed Express (NASDAQ:PETS) Cut to "Hold" at StockNews.com

PetMed Express (NASDAQ:PETS - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Wednesday.

Separately, Morgan Stanley decreased their target price on PetMed Express from $3.50 to $3.20 and set an "underweight" rating on the stock in a research note on Thursday, April 17th.

PetMed Express Stock Performance

Shares of NASDAQ PETS traded up $0.06 during mid-day trading on Wednesday, reaching $3.64. 109,064 shares of the company's stock were exchanged, compared to its average volume of 286,165. The firm has a market capitalization of $75.19 million, a price-to-earnings ratio of 364.36 and a beta of 0.76. PetMed Express has a 52-week low of $2.90 and a 52-week high of $6.85. The company's 50-day moving average is $3.66 and its 200-day moving average is $4.43.

PetMed Express (NASDAQ:PETS - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. As a group, equities analysts predict that PetMed Express will post 0.19 earnings per share for the current fiscal year.

Insider Transactions at PetMed Express

In other PetMed Express news, CEO Sandra Yvette Campos sold 60,463 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $3.31, for a total transaction of $200,132.53. Following the sale, the chief executive officer now owns 578,524 shares in the company, valued at $1,914,914.44. This represents a 9.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.10% of the company's stock.

Institutional Trading of PetMed Express

A number of large investors have recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of PetMed Express in the 1st quarter valued at $295,000. Formidable Asset Management LLC lifted its stake in PetMed Express by 394.5% in the fourth quarter. Formidable Asset Management LLC now owns 135,251 shares of the company's stock valued at $652,000 after buying an additional 107,902 shares during the last quarter. PharVision Advisers LLC acquired a new stake in shares of PetMed Express in the fourth quarter valued at approximately $178,000. Squarepoint Ops LLC increased its holdings in shares of PetMed Express by 41.4% in the 4th quarter. Squarepoint Ops LLC now owns 17,686 shares of the company's stock valued at $85,000 after acquiring an additional 5,180 shares during the period. Finally, Man Group plc raised its position in PetMed Express by 5.5% in the 4th quarter. Man Group plc now owns 145,796 shares of the company's stock valued at $703,000 after purchasing an additional 7,646 shares during the last quarter. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.